Price Alert

Telix Pharmaceuticals Lim... (TLX)

NASDAQ: TLX · Real-Time Price · USD

11.85

0.31 (2.69%)

At close: Aug 18, 2025, 3:59 PM

11.66

-1.60%

Pre-market: Aug 19, 2025, 06:13 AM EDT

Telix Pharmaceuticals Statistics

Share Statistics

Telix Pharmaceuticals has n/a shares outstanding. The number of shares has increased by null% in one year.

Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Institutions (%)	n/a
Shares Floating	n/a
Failed to Deliver (FTD) Shares	2,342
FTD / Avg. Volume	5.08%

Short Selling Information

The latest short interest is 16.95K, so 0.01% of the outstanding shares have been sold short.

Short Interest	16.95K
Short % of Shares Out	0.01%
Short % of Float	0.01%
Short Ratio (days to cover)	1

Valuation Ratios

The PE ratio is 165.07 and the forward PE ratio is 19.95. Telix Pharmaceuticals's PEG ratio is 0.2.

PE Ratio	165.07
Forward PE	19.95
PS Ratio	10.52
Forward PS	3.7
PB Ratio	14.5
P/FCF Ratio	915.85
PEG Ratio	0.2

Financial Ratio History

Enterprise Valuation

Telix Pharmaceuticals has an Enterprise Value (EV) of 8.11B.

EV / Sales	10.36
EV / EBITDA	87.64
EV / EBIT	188.5
EV / FCF	901.52

Financial Position

The company has a current ratio of 2.78, with a Debt / Equity ratio of 1.02.

Current Ratio	2.78
Quick Ratio	2.66
Debt / Equity	1.02
Debt / EBITDA	6.28
Debt / FCF	64.63
Interest Coverage	3.83

Financial Efficiency

Return on Equity is 8.79% and Return on Invested Capital is 6.06%.

Return on Equity	8.79%
Return on Assets	3.29%
Return on Invested Capital	6.06%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	undefined
Asset Turnover	0.52
Inventory Turnover	7.17

Taxes

Income Tax	6.14M
Effective Tax Rate	10.95%

Stock Price Statistics

The stock price has increased by null% in the last 52 weeks. The beta is 2.43, so Telix Pharmaceuticals's price volatility has been higher than the market average.

Beta	2.43
52-Week Price Change	n/a
50-Day Moving Average	15.6
200-Day Moving Average	n/a
Relative Strength Index (RSI)	23.37
Average Volume (20 Days)	46,101

Income Statement

In the last 12 months, Telix Pharmaceuticals had revenue of 783.21M and earned 49.92M in profits. Earnings per share was 0.15.

Revenue	783.21M
Gross Profit	509.68M
Operating Income	82.13M
Net Income	49.92M
EBITDA	92.55M
EBIT	92.55M
Earnings Per Share (EPS)	0.15

Full Income Statement

Balance Sheet

The company has 710.35M in cash and 581.45M in debt, giving a net cash position of 128.9M.

Cash & Cash Equivalents	710.35M
Total Debt	581.45M
Net Cash	128.9M
Retained Earnings	-212.96M
Total Assets	1.52B
Working Capital	587.65M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 43.03M and capital expenditures -34.03M, giving a free cash flow of 9M.

Operating Cash Flow	43.03M
Capital Expenditures	-34.03M
Free Cash Flow	9M
FCF Per Share	0.03

Full Cash Flow Statement

Margins

Gross margin is 65.08%, with operating and profit margins of 10.49% and 6.37%.

Gross Margin	65.08%
Operating Margin	10.49%
Pretax Margin	7.16%
Profit Margin	6.37%
EBITDA Margin	11.82%
EBIT Margin	10.49%
FCF Margin	1.15%

Dividends & Yields

TLX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	0.61%
FCF Yield	0.11%

Dividend Details

Analyst Forecast

The average price target for TLX is $22, which is 102% higher than the current price. The consensus rating is "Buy".

Price Target	$22
Price Target Difference	102%
Analyst Consensus	Buy
Analyst Count	3

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	2.41
Graham Upside	-77.87%

Scores

Altman Z-Score	3.86
Piotroski F-Score	7